TCS, Oracle and DrugLogic Prescribe Safety in a Capsule(TM)
November 13 2007 - 7:06AM
PR Newswire (US)
TCS combines Oracle and DrugLogic solutions to deliver a
comprehensive drug safety and pharmacovigilance solution ORACLE
OPENWORLD 2007, SAN FRANCISCO, Nov 13 /PRNewswire-FirstCall/ --
Tata Consultancy Services (TCS), (BSE:TCS.BOBSE:NSE:BSE:TCS.NS), a
leading global IT services, business solutions and outsourcing firm
and Certified Advantage Partner in the Oracle PartnerNetwork,
announced its collaboration with Oracle and DrugLogic to deliver an
integrated & comprehensive Drug Safety and Pharmacovigilance
Solution - Safety in a Capsule(TM). (Logo:
http://www.newscom.com/cgi-bin/prnh/20020718/ORCLLOGO) In recent
years, pharmacovigilance and drug safety have received greater
public and government scrutiny following a series of high-profile
drug recalls and withdrawals. As a result, pharmaceutical
manufacturers are more focused than ever on improving their ability
to monitor and quickly identify adverse events. Safety in a
Capsule(TM), a joint initiative of TCS, Oracle and DrugLogic,
addresses this need with a pre-packaged safety offering that helps
pharmaceutical manufacturers and biotech companies improve their
ability to monitor events and ensure compliance with increasingly
stringent regulatory requirements. Safety in a Capsule(TM) combines
Oracle's Siebel Contact Center Integration Pack for Oracle Adverse
Event Reporting System, DrugLogic's signal detection solution
'Qscan' and TCS' Knowledge Process Outsourcing (KPO) services to
provide a cost-effective Drug Safety architecture for pro-active
pharmacovigilance. TCS' KPO center in India provides clinical
services for large pharmaceutical companies that include Clinical
Data Management (CDM), Statistical Analysis (SA), Scientific
Communication (SC) and Drug Safety and Pharmacovigilance services.
Safety in a Capsule(TM) will streamline and monitor safety and
surveillance processes followed by pharmaceutical and biotech
companies during the lifecycle of a drug to minimize risks and
costs. The solution will leverage safety analytics for early
insight into a drug's safety profile and rapidly analyze patterns
in adverse events that may indicate emerging drug safety risks pre-
and post-market. Mr. Rajagopal J, Executive Vice President and
Global Head - Consulting; Life Sciences and Medical Devices
Practice, TCS said, "Safety in a Capsule(TM) is a pioneering effort
by TCS and its partners to help pharmaceutical and biotech
companies build a unified drug safety architecture. The solution
will help improve drug safety, minimize risks and reduce costs
while adhering to good pharmacovigilance practices. Safety in a
Capsule(TM) is the result of TCS' focus on providing the best in
class IT services, business solutions and outsourcing services to
customers across the world." "Pharmaceutical and biotech
organizations often store relevant safety data in various
information silos, precluding them from leveraging its full value.
As such, integration and analytics capabilities are critical to
helping pharmaceutical and biotech companies rapidly identify and
assess potential safety issues," said Neil de Crescenzo, Group Vice
President, Healthcare and Life Sciences, Oracle. "Safety in a
Capsule(TM), which incorporates Oracle's Siebel Contact Center
Integration Pack for Oracle Adverse Event Reporting System,
provides a cost-effective architecture that enables the integration
and analysis required to rapidly identify and act on emerging
issues - ultimately advancing drug safety and compliance in a
highly regulated industry." "Integration of Oracle Adverse Event
Reporting System, DrugLogic's Qscan(R)-ERM and TCS services
provides complete safety signal detection and safety surveillance
capabilities within a vendor-supported platform that is
unparalleled in the life sciences industry," said Victor V.
Gogolak, President of DrugLogic. "Drug safety teams can monitor and
analyze - in a single view - legacy, clinical and pre- and
post-market adverse event data. And most significantly, the
validated applications meet regulatory requirements for safety and
pharmacovigilance." About Tata Consultancy Services (TCS) Tata
Consultancy Services is an IT services, business solutions and
outsourcing organization that delivers real results to global
businesses, ensuring a level of certainty no other firm can match.
TCS offers a consulting-led, integrated portfolio of IT and
IT-enabled services delivered through its unique Global Network
Delivery Model(TM), recognized as the benchmark of excellence in
software development. A part of the Tata Group, India's largest
industrial conglomerate, TCS has over 100,000 of the world's best
trained IT consultants in 47 countries. The company generated
consolidated revenues of US $4.3 billion for fiscal year ended 31
March 2007 and is listed on the National Stock Exchange and Bombay
Stock Exchange in India. For more information, visit us at
http://www.tcs.com/. About the Oracle PartnerNetwork Oracle
PartnerNetwork is a global business network of more than 19,500
companies who deliver innovative software solutions based on Oracle
software. Through access to Oracle's premier products, education,
technical services, marketing and sales support, the Oracle
PartnerNetwork program provides partners with the resources they
need to be successful in today's global economy. Oracle partners
are able to offer their customers leading-edge solutions backed by
Oracle's position as the world's largest enterprise software
company. Partners who are able to demonstrate superior product
knowledge, technical expertise and a commitment to doing business
with Oracle qualify for the Certified Partner levels.
http://oraclepartnernetwork.oracle.com/ About DrugLogic
DrugLogic(R), Inc. specializes in developing analytical tools and
enterprise process support systems for managing risks related to
drug safety issues. DrugLogic is dedicated to designing, developing
and delivering products that provide the latest innovations and
state-of-the art solutions in support of pharmacovigilance and drug
safety surveillance practices for both pharmaceutical and biotech
companies. Its proprietary Qscan(TM) product monitors both company
proprietary adverse event data and publicly available data sources.
For more information, visit http://www.druglogic.com/. Trademarks
Oracle is a registered trademark of Oracle Corporation and/or its
affiliates. http://www.newscom.com/cgi-bin/prnh/20020718/ORCLLOGO
http://photoarchive.ap.org/ DATASOURCE: Oracle CONTACT: Mike
McCabe, +1-646-313-4594, Web site: http://www.oracle.com/
http://www.tcs.com/ http://www.druglogic.com/
Copyright